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Hepatocellular adenomas (HCAs) are clinically relevant benign liver lesions that commonly occur in women
on hormonal contraceptives. In this issue of Cancer Cell, Pilati and colleagues present an integrative multi-
‘‘omics’’-based analysis of HCA and identify recurrent genetic alterations associated with adenoma-carci-
noma transition and new drugable targets.Hepatocellular adenomas (HCAs) are
hormone-sensitive monoclonal benign
liver lesions that are associated with the
use of estrogen rich contraceptives or
androgen-containing steroid anabolics.
Most frequently, HCAs develop in noncir-
rhotic livers, displaying a clear gender
disparity with a female/male ratio of 9:1
(Bioulac-Sage et al., 2011). Also, HCAs
are rarely associated with hereditary
metabolic disorders (i.e., glycogen stor-
age defects). Although only a small frac-
tion of HCAs cause clinical symptoms or
undergo malignant transformation, accu-
rate evaluation of this probability is essen-
tial for appropriate treatment.
Significant progress has been achieved
on the basis of mutational analyses as
well as distinct histological and radiolog-
ical features, pioneered by strong French
consortia, resulting in the classification
of HCAs into four subtypes (Nault et al.,
2013a):
(1)Hepatocytenuclear factor 1 (HNF1a)-
mutated HCAs (HHCAs) constitute 30% to
40% of all adenomas mainly character-
ized by disrupted glucose and lipid meta-
bolism, leading to steatosis and down-
regulation of LFABP. Genomic analyses
identified recurrent losses of heterozygos-
ity at chromosome 12q, with subsequent
analyses that revealed biallelic somatic
mutations in the HNF1A gene. HHCAs
are associated with maturity-onset dia-
betes type 3, a monogenic non-insulin-
dependent diabetes (Bluteau et al., 2002).
(2) Telangiectatic/inflammatory ade-
nomas (IHCAs) harbor activating in-frame
somatic mutations in gp130-encodingIL6ST or, less frequently, in GNAS
or STAT3. IHCAs show polymorphic in-
flammatory infiltrates, dystrophic vessels,
and sinusoidal dilatations and constitute
around 40% to 50% of all adenomas
(Rebouissou et al., 2009). The cardinal
feature of IHCAs is the activation of the
JAK/STAT pathway (Pilati et al., 2011);
however, concomitant mutations in b-cat-
enin are observed in up to 50% of IHCAs
(i.e., bIHCA).
(3) b-catenin-mutated adenomas
(bHCAs) constitute approximately 10%
to 15% of all HCAs, displaying cytological
abnormalities including acinar pattern and
cholestatic changes. Activatingmutations
of b-catenin aremainly localized in exon 3.
Interestingly, mutations in the pathway,
while overlapping with other subtypes
(e.g., bIHCA), are mutually exclusive with
HNF1A mutations. bHCAs have the high-
est potential of malignant transformation
into hepatocellular carcinoma (HCC),
ranging from 0%–18% and representing
two thirds of all transformed HCAs
(Farges et al., 2011). Interestingly, preva-
lence of malignancy in bHCA is ten times
higher in men than women and is asso-
ciated with metabolic changes. Identi-
fication of this subtype has the most
important clinical implications for patient
management (e.g., withdrawal of andro-
gens or resection).
(4) Around 10% of HCAs show no spe-
cific morphological or immunophenotypi-
cal patterns and are, therefore, termed
unclassified HCA (UHCA).
In this issue of Cancer Cell, Pilati et al.
(2014) report further refinement of the mo-Cancer Cellecular understanding of HCAs by using
integrative genomic analyses combining
multiple molecular layers. Due to a large
collection of representative HCA samples
and theuseof next-generationsequencing
in combination with other genomic tech-
nologies, the results provide several
exciting clinical as well as mechanistic in-
ferences (Figure 1).
The study included 250 tumors from
195 patients and is the largest to date.
The cohort was well balanced regarding
gender (male:female, 1:6), etiology (84%
oral contraceptives), and subtypes
(HHCA, 29%; bHCA, 14%; bIHCA, 16%;
IHCA, 31%; UHCA, 10%). The study also
included 18 HCAs with malignant trans-
formation into HCC. The authors initially
screened 35 tumors by a whole-exome
sequencing approach. The analyses
yielded the identification and subsequent
validation of 264/508 somatic mutations
as potentially protein altering. Interest-
ingly, compared to other malignant solid
tumorssuchascolon, lung, andpancreatic
cancerswith an average of 33 to 66protein
damaging mutations (Vogelstein et al.,
2013) and, in particular, HCC with around
41 mutations, the genomes of HCAs
appear relatively stable with an average
rate of damaging mutations of 7.5. Among
the mutations, only CTNNB1, IL6ST,
HNF1A, andFRKwere recurrentlymutated
in at least threeHCAs.Of note, paired ana-
lyses of different tumors in the same
patients suggested an independent devel-
opment of the lesions, potentially indi-
cating that multiple biopsiesmight bewar-
ranted in patients with multifocal disease.l 25, April 14, 2014 ª2014 Elsevier Inc. 409
Figure 1. Several Risk Factors Predicting the Biological Traits of HCAs and Associated
Complications, i.e., Hemorrhage and Malignant Transformation, Have Been Identified
Overall, HHCAs possess a relatively low risk of malignant transformation. Therefore, surveillance by imag-
ing (e.g., MRI) seems justified. b-catenin mutations, regardless of the subtype, increased adenoma-
carcinoma transition. The study by Pilati et al. (2014) further identifies a fraction of IHCA with drugable
mutations in FRK and JAK1 that could benefit from chemoprophylaxis with the SRC inhibitor dasatinib
or the JAK inhibitor ruxolitinib, respectively. Resection should be evaluated in all large HCAs (>5 cm) or
HCAs that develop in male patients regardless of the molecular subtype. In small HCAs (<5 cm), the de-
cision for surgery should be based on the presence of b-catenin mutation. Furthermore, TERT mutations
confer a higher risk of malignant transformation in b-catenin mutated HCAs. Given the clinical implication
from the present work and the importance of histological and detailed molecular evaluation for the rational
and individualized management of HCAs, the need for obtaining a liver biopsy is imperative.
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genes in the whole cohort not only nicely
recapitulated the known driver mutations
of the corresponding subtype, but also
confirmed the presence of previously
unrecognized somatic mutations in FRK,
a member of the SRC kinase family, as
well as JAK1. A total of 12 IHCA/bIHCA
showed activating FRK mutations in two
hot spots of the tyrosine kinase catalytic
domain, thereby constituting the second
most frequent alterations in IHCA. Gain-
of-function analyses of mutant FRK
induced a strong inflammatory response
in a STAT3-dependent manner, but
independent of interleukin-6 exposure.
Consistently, administration of the SRC
inhibitor dasatinib significantly reduced
the oncogenic activity of FRK mutants,
suggesting that the proliferative charac-
teristics of these IHCAs are mainly driven
by FRK-dependent oncogene addiction
and are likely to benefit from SRC inhibi-
tion. Furthermore, the JAK1 mutation in
one IHCA also induced STAT3 activation.
Interestingly, protein-altering JAK1 muta-
tions in S703I and S729C have been pre-
viously recognized in around 9% of HCCs410 Cancer Cell 25, April 14, 2014 ª2014 Els(Kan et al., 2013). In this study JAK1-
mutated hepatoma cells significantly re-
sponded to in vitro exposure to the
JAK1/2 inhibitor ruxolitinib. These results
suggest that the JAK1 inhibition might
also be an effective therapeutic approach
in the affected IHCAs.
The authors also performed integrative
analyses of copy-number alterations
and methylome profiling and accurately
recapitulated the different molecular
subclasses. While the overall frequency
of copy-number alterations was rela-
tively low, several recurrent chromosomal
changes specific for HHCA were identi-
fied. Methylome analyses showed that
DNA methylation particularly affect gene
expression in this subtype. Furthermore,
a progressive increase in chromosomal
instability as well as somatic mutations
in addition to global hypomethylation
was observed during transition from
HCA into HCC. However, more detailed
investigations are needed to determine if
epigenetic changes predispose specific
genetic alterations or vice versa (Jones
and Baylin, 2007). Nevertheless, muta-
tional analyses confirmed that mutationsevier Inc.in CTNNB1 are a prerequisite for the tran-
sition into HCC. However, while results
from one patient suggested that CTNNB1
mutations occur relatively early, addi-
tional genetic alterations are necessary
to promote tumor progression, indicating
a two-hit model of malignant transforma-
tion in HCA. Interestingly, acquisition
of activating somatic TERT promoter mu-
tations appears to be a major genetic
driver promoting the adenoma-carcinoma
sequence in b-catenin-activated HCA.
These investigations are in agreement
with recent findings indicating that TERT
promoter activation are among the
earliest and most frequent alterations
in HCC (Nault et al., 2013b). Therefore,
bHCA and bIHCA should be closely moni-
tored for both alterations to effectively
guide treatment decisions.
In summary, the present work does not
only generate prognostic information for
patients at risk for malignant transforma-
tion, but also identifies molecular targets
for novel therapeutic approaches in HCA
and predicts a corresponding subclass
of patients that are likely to benefit
from a specific chemoprophylaxis. This
is achieved by effective integration of ge-
netic and genomic characteristics of the
neoplastic lesions, and the current study
is a splendid example of how the bench-
to-bedside/translational use of next-gen-
eration technologies can directly impact
and guide clinical decision making.ACKNOWLEDGMENTS
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It is unclear whether the antiproliferative/proapoptotic activity of oncogenes can be pharmacologically
reactivated in cancer cells. In this issue of Cancer Cell, Liu and colleagues report that a proteasome inhibitor
reactivates an MLL-AF4 controlled antitumor program to kill leukemia cells in an oncogene dose- and cell
type-dependent manner.Oncogenes, such as constitutively acti-
vated Ras, can drive tumorigenesis;
therefore, it was initially unexpected
that oncogenes also possess contex-
tual antitumor activities like causing
apoptosis and cell senescence (Lowe
et al., 2004; Serrano et al., 1997). It was
later found that while activated onco-
genes initially trigger antitumor pro-
cesses in cells, they eventually lose their
antitumor activity and drive tumorigen-
esis in a temporal and contextual manner
(Lowe et al., 2004). However, it remains
unclear whether the often hidden anti-
tumor action of a particular oncogene
can be reactivated pharmacologically
and utilized to specifically target cancer
cells. A definitive answer to this question
would unravel the mechanisms choreo-
graphing the ‘‘Jekyll and Hyde’’ actions
of oncogenes, i.e., antitumor versus
oncogenic activity, and shed light on
how to improve cancer therapy. In this
regard, Liu et al. (2014) report in this
issue of Cancer Cell that when pro-B
mixed lineage leukemia (MLL) cells are
treated with a proteasome inhibitor, the
MLL-AF4 protein level increases and
subsequently triggers an antitumor pro-
gram in concert with the pro-B cell-specific transcription factor PAX5. This
antitumor program induces both the
antiproliferative p27kip, encoded by
CDKN1B and proapoptotic caspase-8,
and ultimately leads to specific suppres-
sion of pro-B MLL-AF4 leukemia.
MLL is classified as a group of acute
leukemias, often refractory to chemo-
therapy and with poor overall prognosis,
that expresses one of a number of
different leukemogenic fusion genes con-
sisting of the 50 part ofMLL fused to one of
many genes from other chromosomes
(Krivtsov and Armstrong, 2007). MLL
fusion proteins (MLL-FPs), in concert
with the wild-type MLL protein (Thiel
et al., 2010), drive leukemogenesis mainly
through inducing the expression of HOX
genes (Ayton and Cleary, 2003; Milne
et al., 2002). Expression of MLL-AF4
tends to cause B cell lymphoblastic leuke-
mia (Krivtsov et al., 2008).
The authors previously reported that
MLL-FPs are regulated in leukemia cells
via proteolysis by the proteasome (Liu
et al., 2007), a molecular machine special-
ized in degrading proteins. Unlike many
oncogenes that are highly expressed in
cancer cells, MLL-AF4 tends to be ex-
pressed at low levels in leukemia cells.To address this distinct feature of MLL-
AF4, Liu and colleagues investigated
whether increased levels of MLL-AF4
leads to suppression of leukemia cells.
They treated various human leukemia
cell lines with the proteasome inhibitor
bortezomib, which is approved for the
treatment of multiple myeloma, to inhibit
MLL-AF4 degradation. Many key proteins
controlling cell survival and proliferation
are regulated by proteasome-mediated
proteolysis, and their levels are often
increased by treatment with bortezomib
(Frankland-Searby and Bhaumik, 2012).
Bortezomib increased levels of wild-type
MLL as well as MLL fusion proteins in all
tested leukemia cell lines. Interestingly,
pro-B MLL leukemia cell lines were more
sensitive to bortezomib-induced G2/M
cell cycle arrest and apoptosis when
compared to non-MLL pro-B leukemia
cell lines, whereas all of the cell lines
showed similar sensitivity to other
chemotherapeutic agents. Based on
these findings, the authors suspected
that MLL-AF4 participates in bortezo-
mib-induced cytotoxicity in the pro-B
MLL leukemia cells.
To explore this possibility, they demon-
strated that selective knockdown ofl 25, April 14, 2014 ª2014 Elsevier Inc. 411
